Page 1

GENFIT TOWARDS BETTER MEDICINE PRESS RELEASE GENFIT Reports First Half - Year 2021 Financial Results and Provides Corporate Update Financial highlights ○ Cash and cash equivalents totaled € 104 million as of June 30 , 2021 ( including € 11 million non - dilutive financing obtained in the first half 2021 ) Net income totaled € 9 million for the first half 2021 , due to a one - off revenue following the successful outcome of the convertible debt restructuring in January and the OCEANES conversions in the first quarter Positive developments with elafibranor in PBC ( ELATIVE ™ Phase 3 ) ○ Foresee completion of enrolment in first quarter 2022 Timeline for potential FDA filing now estimated in second half 2023 , based on a successful Phase 3 trial outcome New clinical data expected in several indications , starting as early as the third quarter 2022 ○ NTZ in ACLF ( Phase 1 ) O Elafibranor in PSC ( Phase 2 PoC ) O Elafibranor in PBC ( exploratory and complementary study to ELATIVE ™ in treatment - naïve patients ) Lille , France ; Cambridge , MA ; September 29 , 2021 - GENFIT ( Nasdaq and Euronext : GNFT ) , a late - stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases , today announced its first half - year financial results and provided a corporate update . The Half Year Business and Financial Report is available to the public and was filed with the French Autorité des marchés financiers ( French Financial Markets Authority ) today . The condensed consolidated financial statements are included in this press release and the complete financial statements are available on the " Investors " page of the GENFIT website . Conference Call in English on September 29 , 2021 at 4:15 pm EDT | 9:15 BST | 10:15 pm CEST , and in French on September 30 , 2021 at 7:30 am CEST | 1:30 am EDT GENFIT | 885 Avenue Eugène Avinée , 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1